2018 annual financial data
Halozyme Therapeutics 2018 Operating margin
Direct answer
Operating margin was -45.65%.
Operating income was -69,330,000 USD and net income was -80,330,000 USD.
Operating cash flow was -49,500,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 151,862,000 USD
- Operating income
- -69,330,000 USD
- Net income
- -80,330,000 USD
- Operating cash flow
- -49,500,000 USD